Pancreatic Cancer Research

ResearcherThe University of Texas at San Antonio Health Science CenterActive in the last 2 years

Daruka Mahadevan

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-7129-5593; OpenAlex author ID A5101638085. Sources: OpenAlex.

Their work

Papers
9 (first author 1, last author 4)
Trials
0
Grants
0
Labs led
1
Collaborators
17
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: 1 paper · 2014: none · 2015: none · 2016: none · 2017: none · 2018: none · 2019: 3 papers · 2020: 1 paper · 2021: none · 2022: 2 papers · 2023: none · 2024: 1 paper

Papers 9

  1. ERBB2 (HER2) amplifications and co-occurring KRAS alterations in the circulating cell-free DNA of pancreatic ductal adenocarcinoma patients and response to HER… Co-author DOI 10.3389/fonc.2024.1339302↗
  2. A multicenter phase 1/2 study investigating the safety, pharmacokinetics, pharmacodynamics and efficacy of a small molecule antimetabolite, RX-3117, plus nab-p… Co-author DOI 10.1007/s10637-021-01164-9↗
  3. Pharmacotherapeutic options for pancreatic ductal adenocarcinoma. Co-author DOI 10.1080/14656566.2022.2149322↗
  4. In Silico analyses of host immunity and stroma provide prognostic factors in early stage pancreatic ductal adenocarcinoma (PDAC). First author DOI 10.21037/atm.2020.03.37↗
  5. Carcinoembryonic antigen cell adhesion molecule 6 (CEACAM6) in Pancreatic Ductal Adenocarcinoma (PDA): An integrative analysis of a novel therapeutic target. Last author DOI 10.1038/s41598-019-54545-9↗
  6. Therapeutic trends in pancreatic ductal adenocarcinoma (PDAC). Last author DOI 10.1080/13543784.2019.1557145↗
  7. Everolimus for the treatment of advanced pancreatic ductal adenocarcinoma (PDAC). Last author DOI 10.1080/13543784.2019.1632289↗
  8. Phase I trial of AEG35156 an antisense oligonucleotide to XIAP plus gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma. Co-author DOI 10.1097/coc.0b013e3182467a13↗
  9. An analog of withaferin A activates the MAPK and glutathione "stress" pathways and inhibits pancreatic cancer cell proliferation. Last author DOI 10.3109/07357907.2011.626478↗

Closest collaborators

The 17 strongest of 17 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Hani M. Babiker · 4 shared papers, 2019–2022 · strength 0.57
  2. Sreenivasa Rao Chandana · 3 shared papers, 2019–2022 · strength 0.43
  3. Kabir Mody · 2 shared papers, 2022–2024 · strength 0.37
  4. Mitesh J. Borad · 2 shared papers, 2022 · strength 0.29
  5. Alejandro Recio‐Boiles · 2 shared papers, 2019–2022 · strength 0.27
  6. Madison H. Williams · 1 shared paper, 2020 · strength 0.24
  7. Afsaneh Barzi · 1 shared paper, 2024 · strength 0.22
  8. Andrea Wang‐Gillam · 1 shared paper, 2024 · strength 0.22
  9. Muhammad Sardar · 1 shared paper, 2022 · strength 0.15
  10. Andrea J. Bullock · 1 shared paper, 2022 · strength 0.14
  11. Allyson J. Ocean · 1 shared paper, 2022 · strength 0.14
  12. Ali McBride · 1 shared paper, 2019 · strength 0.11
  13. Jayati L. Chakrabarti · 1 shared paper, 2019 · strength 0.09
  14. Glen J. Weiss · 1 shared paper, 2013 · strength 0.04
  15. Ramesh K. Ramanathan · 1 shared paper, 2013 · strength 0.04
  16. Daniel D. Von Hoff · 1 shared paper, 2013 · strength 0.04
  17. Xiaobing Liu · 1 shared paper, 2011 · strength 0.03

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.